Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.62 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.59 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.59 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.59 |
| ▸ | TERT | O14746 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | DTYMK | P23919 | 4/20 | 0.54 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.48 |
| ▸ | TYMS | P04818 | 1/20 | 0.48 |
| ▸ | TK1 | P04183 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29519934 | 1.00 | F2 (0.62) | F2P2RY2P2RY4P2RY6TERT | |
| SCHEMBL30211177 | 1.00 | F2 (0.62) | F2P2RY2P2RY4P2RY6TERT | |
| SCHEMBL29652743 | 1.00 | F2 (0.62) | F2P2RY2P2RY4P2RY6TERT | |
| SCHEMBL29357819 | 1.00 | F2 (0.62) | F2P2RY2P2RY4P2RY6TERT | |
| SCHEMBL30092339 | 1.00 | F2 (0.62) | F2P2RY2P2RY4P2RY6TERT | |
| SCHEMBL29372542 | 1.00 | F2 (0.62) | F2P2RY2P2RY4P2RY6TERT | |
| SCHEMBL31103632 | 0.96 | F2 (0.67) | F2P2RY2P2RY4P2RY6TERT | |
| SCHEMBL30055250 | 0.96 | F2 (0.67) | F2P2RY2P2RY4P2RY6TERT | |
| SCHEMBL29551345 | 0.96 | F2 (0.67) | F2P2RY2P2RY4P2RY6TERT | |
| SCHEMBL29552315 | 0.96 | F2 (0.67) | F2P2RY2P2RY4P2RY6TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 641 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743111-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING FUNGAL INFECTIONS | Rutgers, the State University of New Jersey (US) | 2026-05-20 | — | — | EP | claimed |
| WO-2026102413-A1 | MULTIVALENT TUBERCULOSIS VACCINE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-15 | — | — | WO | claimed |
| CN-122031675-A | TLR9+HA201 composite adjuvant and preparation method and application thereof | 华诺泰生物医药科技(成都)有限公司 | 2026-05-15 | — | — | CN | claimed |
| EP-4704888-A2 | COMPOSITIONS CONTAINING POLYNUCLEOTIDE AND POLYPEPTIDE AMPHIPHILES AND METHODS OF USE THEREOF | Elicio Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260048081-A1 | COMBINED TREATMENT COMPOSITION FOR TUMOR TREATMENT AND COMBINED TREATMENT METHOD | ADVACCINE SUZHOU BIOPHARMACEUTICALS CO LTD (CN) | 2026-02-19 | — | — | US | claimed |
| US-20260049057-A1 | OPIOID HAPTENS, CONJUGATES, VACCINES, AND METHODS OF GENERATING ANTIBODIES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2026-02-19 | — | — | US | claimed |
| US-20260007741-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINES | AKAGERA MEDICINES, INC. (US) | 2026-01-08 | — | — | US | claimed |
| US-12514865-B2 | Biomaterial-based antigen free vaccine and the use thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-01-06 | — | — | US | claimed |
| US-12491237-B2 | Vaccine compositions and methods for the treatment and prevention of urinary tract infections | DUKE UNIVERSITY (US) | 2025-12-09 | — | — | US | claimed |
| US-12472209-B2 | Neural stem cell delivery of therapeutic agents | CITY OF HOPE (US) | 2025-11-18 | — | — | US | claimed |
| CN-114887049-A | Immunologic adjuvant composition, cancer vaccine based on composition and application of immunologic adjuvant composition | 苏州尔生生物医药有限公司 | 2022-08-12 | — | — | CN | claimed |
| CN-112957475-B | Composition for preventing and/or treating tumors and application thereof | 李文峰 | 2022-07-22 | — | — | CN | claimed |
| EP-4003517-A1 | ADOPTIVE TRANSFER OF PLASMACYTOID DENDRITIC CELLS TO PREVENT OR TREAT HAIR LOSS | Tufts Medical Center, Inc. (US) | 2022-06-01 | — | — | EP | claimed |
| CN-114558146-A | Immune exosome nanoparticle loaded with traditional Chinese medicine self-assembly micelle as well as preparation method and application thereof | 南京中医药大学 | 2022-05-31 | — | — | CN | claimed |
| WO-2022087156-A1 | PROINFLAMMATORY PRODRUGS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-04-28 | — | — | WO | claimed |
| US-20220111039-A1 | IMMUNOGENIC CONSTRUCTS, COMPOSITIONS, AND METHODS FOR INDUCING IMMUNE RESPONSE | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-04-14 | — | — | US | claimed |
| US-20220096526-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF OCULAR DISEASES AND CONDITIONS | TUFTS MEDICAL CENTER, INC. | 2022-03-31 | — | — | US | claimed |
| US-20220096627-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS THROUGH STIMULATED INNATE IMMUNITY IN COMBINATION WITH ANTIVIRAL COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-03-31 | — | — | US | claimed |
| US-20220081400-A1 | OPIOID HAPTENS, CONJUGATES, VACCINES, AND METHODS OF GENERATING ANTIBODIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-17 | — | — | US | claimed |
| CN-108300692-B | Method for preparing HPV antigen specific cytotoxic T lymphocyte | 吉林省拓华生物科技有限公司 | 2022-02-15 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048081-A1 | COMBINED TREATMENT COMPOSITION FOR TUMOR TREATMENT AND COMBINED TREATMENT METHOD | CD74, STING1, TP53 | F2 3903/4885P2RY2 3946/4885P2RY4 4180/4885 |
| US-12472209-B2 | Neural stem cell delivery of therapeutic agents | NES, TSG101, ELAVL1 | F2 4884/4885P2RY2 285/4885P2RY4 311/4885 |
| US-20260007741-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINES | TLR9, TLR3, TLR8 | F2 3735/4885P2RY2 265/4885P2RY4 335/4885 |
| US-20220081400-A1 | OPIOID HAPTENS, CONJUGATES, VACCINES, AND METHODS OF GENERATING ANTIBODIES | OPRM1, OPRK1, OPRL1 | F2 3796/4885P2RY2 2788/4885P2RY4 2313/4885 |
| US-20260049057-A1 | OPIOID HAPTENS, CONJUGATES, VACCINES, AND METHODS OF GENERATING ANTIBODIES | OPRD1, ANTXR2, OPRM1 | F2 518/4885P2RY2 1152/4885P2RY4 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.